AL102
Phase 2/3Active 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Desmoid
Conditions
Desmoid, Desmoid Tumor
Trial Timeline
Mar 30, 2021 → Oct 1, 2026
NCT ID
NCT04871282About AL102
AL102 is a phase 2/3 stage product being developed by Immunome for Desmoid. The current trial status is active. This product is registered under clinical trial identifier NCT04871282. Target conditions include Desmoid, Desmoid Tumor.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04871282 | Phase 2/3 | Active |
Competing Products
1 competing product in Desmoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sirolimus | Pfizer | Phase 1/2 | 40 |